The new device from Arizona-based Corvention was built to withstand the extreme pressures associated with treating severely calcified valves. 

The company's Seismiq platform has already gained FDA approval for treating PAD. This new analysis highlights its potential to treat calcified coronary lesions during PCI procedures.

The American Society of Nuclear Cardiology visited Capitol Hill to advocate for a variety of issues. Cardiovascular Business spoke to the group's president to learn more.